VXRT
Vaxart, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.50
+0.51%Aug 9, 2026, 20:04 UTC
Vaxart reported positive 12-month safety data from the 400-participant Sentinel cohort of its Phase II-B COVID-19 vaccine trial during its Q2 earnings call.
Source:Jul 20, 2026, 10:02 UTC
Vaxart held its 2026 Annual Meeting of Stockholders, where investors re-elected the company's full slate of directors.
Jul 2, 2026, 00:00 UTC
Vaxart entered into a cooperation agreement with a stockholder group, withdrawing director nominations and agreeing to appoint an independent director and adopt new policies.
Source: